News & Updates
Filter by Specialty:
Fake news discourages social distancing, promotes snake oil measures
People who are exposed to online misinformation about the coronavirus disease 2019 (COVID-19) become more likely to engage in unscientific practices, such as rinsing their noses with saline or eating more garlic, according to a recent Singapore study. On the other hand, misinformation discourages evidence-based prevention strategies, such as social distancing.
Fake news discourages social distancing, promotes snake oil measures
10 Mar 2022Hyperbaric oxygen therapy promising for T2DM complications
Hyperbaric oxygen therapy (HBOT) may be an effective treatment approach for several complications of type 2 diabetes mellitus (T2DM), such as nephropathy and retinopathy, a recent study has found.
Hyperbaric oxygen therapy promising for T2DM complications
10 Mar 2022Delamanid-based regimens work against multidrug-resistant tuberculosis
The use of delamanid-containing regimens is safe and effective in the management of multidrug-resistant tuberculosis (MDR-TB), with high culture conversion and treatment success rates despite extensive resistance patterns, according to the results of a meta-analysis.
Delamanid-based regimens work against multidrug-resistant tuberculosis
10 Mar 2022Continuing enzalutamide after progression improves PFS in mCRPC
In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.
Continuing enzalutamide after progression improves PFS in mCRPC
09 Mar 2022New NSAID patch matches diclofenac gel for pain management in knee osteoarthritis
The novel topical nonsteroidal anti-inflammatory drug (NSAID) S-flurbiprofen plaster provides relief from pain that appears similar to that achieved with diclofenac gel in patients with knee osteoarthritis, in addition to being well tolerated, according to data from an open-label, noninferiority phase III study.